Tumor glycolytic profiling through ¹⁸F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC.

ABSTRACT:

Background

A significant proportion of patients with non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with increased glycolysis is a hallmark of cancer and is involved in immune evasion, we used ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography (¹⁸F-FDG PET/CT) to evaluate the baseline glycolytic parameters of patients with advanced NSCLC submitted to ICIs, and assessed their predictive value.

Methods

¹⁸F-FDG PET/CT results in the 3 months before ICIs treatment were included. Maximum standardized uptake values, whole metabolic tumor volume (wMTV), and whole-body total lesion glycolysis (wTLG) were evaluated. Cutoff values for high or low glycolytic ca

SUBMITTER: Silva SB 

PROVIDER: S-EPMC9730014 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature